Topiramate
- Generic Name
- Topiramate
- Brand Names
- Eprontia, Qsymia, Qudexy, Topamax, Trokendi
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21NO8S
- CAS Number
- 97240-79-4
- Unique Ingredient Identifier
- 0H73WJJ391
- Background
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
...
- Indication
Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associat...
- Associated Conditions
- Alcohol Dependency, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Generalized Tonic-Clonic Seizures, Lennox-Gastaut Syndrome, Migraine, Moods Disorders, Partial-Onset Seizures, Seizures, Weight
- Associated Therapies
- Chronic Weight Management therapy, Weight Reduction
A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
- Conditions
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 409
- Registration Number
- NCT00266604
A Study of the Efficacy and Safety of Topiramate Treatment in Patients With Epilepsy
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 51
- Registration Number
- NCT00266591
An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 38
- Registration Number
- NCT00261469
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-04-28
- Target Recruit Count
- 211
- Registration Number
- NCT00253175
Topiramate in the Treatment of Pathological Gambling
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 42
- Registration Number
- NCT00245583
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome
- Conditions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2007-12-10
- Target Recruit Count
- 90
- Registration Number
- NCT00243984
- Locations
- 🇺🇸
Akron General Medical Center, Akron, Ohio, United States
🇺🇸Forum Health/Northside Medical Center, Youngstown, Ohio, United States
🇺🇸St. Elizabeth Health Center, Youngstown, Ohio, United States
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 363
- Registration Number
- NCT00240721
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 90
- Registration Number
- NCT00236743
A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 223
- Registration Number
- NCT00236496
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 47
- Registration Number
- NCT00236873
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.